ProCE Banner Activity

Interactive Decision Support Tool: Treatment Selection for Patients With Advanced Endometrial Cancer

Tool

Use this Interactive Decision Support Tool to compare your management of patients with advanced endometrial cancer with those of 5 renowned gynecologic oncology experts.

Released: September 13, 2022

Expiration: September 12, 2023

No longer available for credit.
Begin Activity

Share

Faculty

Maria Bell

Maria Bell, MD, MPH, MBA

Medical Director of Research
Gynecologic Oncologist
Sanford Health
Sioux Falls, South Dakota

Hye Sook Chon

Hye Sook Chon, MD

Associate Professor
Clinical Trial Medical Director
Department of Gynecologic Oncology
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida

Linda R. Duska

Linda R. Duska, MD, MPH, FACOG, FACS, FASCO

Gynecologic Oncologist
Department of OB GYN/Gynecologic Oncology
University of Virginia School of Medicine
Charlottesville, Virginia

Ritu Salani

Ritu Salani, MD, MBA

Professor and Division Director
OB/GYN and Gynecologic Oncology
University of California, Los Angeles
Los Angeles, California

Shannon N. Westin

Shannon N. Westin, MD, MPH

Associate Professor
Division of Surgery
Department of Gynecologic Oncology and Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

GlaxoSmithKline

Merck Sharp & Dohme Corp.

Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme

Faculty Disclosure

Contributing Author

Maria Bell, MD, MPH, MBA

Medical Director of Research
Gynecologic Oncologist
Sanford Health
Sioux Falls, South Dakota

Hye Sook Chon, MD

Associate Professor
Clinical Trial Medical Director
Department of Gynecologic Oncology
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida

Hye Sook Chon, MD, has no relevant financial relationships to disclose.

Linda R. Duska, MD, MPH, FACOG, FACS, FASCO

Gynecologic Oncologist
Department of OB GYN/Gynecologic Oncology
University of Virginia School of Medicine
Charlottesville, Virginia

Linda R. Duska, MD, MPH, FACOG, FACS, FASCO: researcher (paid to institution): Aduro Biotech Inc, ARCH Oncology, CE3 Inc, Clinipace Inc, Corcept Therapeutics, Eisia, GlaxoSmithKline, Harpoon Therapeutics, K-Group Beta, Leap Therapeutics, Lycera, Ludwig Institute for Cancer Research, Merck Sharp and Dohme, NRG, OncoQuest, Pfizer, PharmaMar, Plexxikon, Psi Pharma Support America, Seattle Genetics, Syndax; data safety monitoring committee: Agenus, Inovio.

Ritu Salani, MD, MBA

Professor and Division Director
OB/GYN and Gynecologic Oncology
University of California, Los Angeles
Los Angeles, California

Ritu Salani, MD, MBA: consultant/advisor/speaker: GSK, Merck, Regeneron, Seagen.

Shannon N. Westin, MD, MPH

Associate Professor
Division of Surgery
Department of Gynecologic Oncology and Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas